Introduction
============

Growth hormone insensitivity (GHI) is characterised by growth failure, IGF1 deficiency and normal or elevated GH levels. GHI encompasses a spectrum of genetic, phenotypic and biochemical abnormalities associated with growth failure ([@bib1], [@bib2]). Monogenic defects of the GH-IGF1 axis leading to GHI have been identified in the*GHR* ([@bib3]), *STAT5B* ([@bib4]), *IGFALS* ([@bib5]), *PAPPA2* ([@bib6]) and *IGF1* ([@bib7]) genes.

Splicing is the process by which introns are precisely identified and excised with the remaining exons united to form a translatable message ([@bib8]). Intronic DNA frequently encodes potential exonic sequences ([@bib9]). These 'pseudoexons' are sequences between 50 and 300 nucleotides in length with apparently viable 5′ and 3′ splice sites ([@bib10], [@bib11]). Under normal circumstances, they are actively suppressed and not recognised by the splicing machinery ([@bib10], [@bib12], [@bib13], [@bib14], [@bib15]). However, point mutations in intronic DNA sequences can lead to the creation of new donor (5′), acceptor (3′) splice or branch sites and activation of 'pseudoexons'. This often occurs within 100 nucleotide bases of the canonical splice site resulting in the inclusion of intronic sequences immediately flanking the exonic sequence ([@bib16]). Inclusion of intronic sequences by aberrant splicing is a recognised rare cause of several genetic diseases including neurofibromatosis type 1, cystic fibrosis, Duchenne and Becker muscular dystrophies ([@bib8], [@bib17]).

The intronic growth hormone receptor (*GHR*) pseudoexon (6Ψ) mutation was first reported in 2001 in two sets of siblings from a highly consanguineous Pakistani family with growth failure and features of relatively mild GHI ([@bib18]). In 2007, an additional seven 6Ψ patients were reported with a wider range of short stature (SS) phenotypes ([@bib19]). In 2013, Walenkamp *et al*. described two further 6Ψ patients with growth failure followed by partial catch-up growth without treatment ([@bib20]). We recently reported the spectrum of clinical and biochemical features in 20 6Ψ subjects, which included eleven previously reported individuals and nine additional patients ([@bib21]).

The *GHR* 6Ψ mutation (c.618+792A\>G) is a homozygous point mutation in the final nucleotide of the pseudoexon, altering the 5′ pseudoexon splice site in intron 6 of the *GHR* gene. This results in activation of the pseudoexon sequence, efficient splicing and inclusion of an additional 108 bases between exons 6 and 7. This results in the inclusion of 36 amino acids in the extracellular domain of the GHR protein ([@bib18]), and functional work demonstrated that the mutant GHR protein impaired trafficking rather than signalling ([@bib22]).

Under normal circumstances, the *GHR* pseudoexon is disregarded, that is, not spliced into the mature *GHR* mRNA. Previous work confirmed that binding of heterogenous nuclear ribonucleoprotein E1 (hnRNP E1) and U1 small nuclear ribonucleoprotein (snRNP) to the pre-spliceosomal complex prevented 6Ψ inclusion ([@bib8]).

*GHR* 6Ψ mutation patients exhibit a wide spectrum of clinical and biochemical variability, even between individuals within the same kindred ([@bib21]). The height SDS of 20 *GHR* 6Ψ patients previously described ([@bib21]) varied between −1.7 and −5.9 with IGF1 SDS between −1.0 and −6.8. Additionally, 50% patients had 'classical' GHI facial features and the remainder had completely normal facial appearance ([@bib21]).

Splice mutations may not always be 100% efficient in causing aberrant splicing, and normal (WT) and mutant transcripts may exist concurrently due to competitive use of normal and mutant splice sites. Previous data suggested that, alongside the abnormally spliced *GHR* transcript, a small amount of normally spliced WT *GHR* mRNA was present in*GHR* 6Ψ patients ([@bib18]).

Analysis of cDNA of patients carrying different splice mutations of the same gene have shown that multiple abnormal splicing events occur alongside the production of the normal splice product, leading to a spectrum of phenotypes ([@bib23], [@bib24], [@bib25]). However, transcript variability has not previously been investigated in individuals with identical splice mutations.

The range of phenotypes observed in patients with the *GHR* 6Ψ mutation may be related to the presence of transcript heterogeneity, that is, the ratio of abnormal (mutant) to normal (WT) *GHR* transcript. Genetic and environmental factors may also play a role in defining this ratio ([@bib19]). We investigated for the first time, whether *GHR* gene transcript heterogeneity and/or concurrent defects in other known short stature genes contributed to the observed clinical variability of 6Ψ subjects.

Subjects and methods
====================

Subjects
--------

The subjects were diagnosed with homozygous intronic *GHR* 6Ψ mutations at our centre between 2001 and 2014 ([@bib18], [@bib19], [@bib21]). The referring physicians completed a proforma detailing the clinical and biochemical details at the time of DNA sampling for genetic analysis ([@bib21]) and was prior to starting any growth promoting therapy. Height measurements were obtained using a wall-mounted stadiometer. Height was expressed as SDS according to the appropriate UK-WHO growth national standards ([@bib26], [@bib27]). IGF1 values were expressed as SDS based on the age and sex appropriate ranges provided by the host institution.

Fibroblast culture
------------------

Dermal fibroblasts from four *GHR* 6Ψ subjects (patients 1--4) from two consanguineous Pakistani families were obtained by punch skin biopsies, which were performed according to established protocols ([@bib28], [@bib29]) after written informed consent was obtained. Control human fibroblasts (normal neonatal male dermal fibroblast cell line) were obtained from American Type Culture Collection (ATCC). Fibroblast cells were cultured in 75 cm^2^ cell culture flasks (Greiner Bio-One, Germany) in High Glucose-DMEM (Sigma-Aldrich) supplemented with 20% foetal bovine serum (Invitrogen), 50 units/mL penicillin and 50 μg/mL streptomycin.

Reverse-transcriptase PCR (RT-PCR)
----------------------------------

RNA was extracted from fibroblast cell lines using the RNAEasy kit (Qiagen) as per the manufacturer's instructions. One microgram RNA was reverse transcribed using the Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV RT) mix (Thermo Fisher Scientific) according to manufacturer's protocol. cDNA products from four patients and one control subject were amplified using the following intron skipping primers ([Fig. 1A](#fig1){ref-type="fig"}): Figure 1Reverse transcriptase PCR (RT-PCR) of WT and mutant transcripts in the 6Ψ and control subjects. (A) Schematic diagram of the *GHR* gene showing the position of the 6Ψ pseudoexon and intron skipping primers. 6Ψ, mutant pseudoexon transcript; WT, wild type *GHR* transcript. (B) 2% agarose gel showing products of RT-PCR Reaction 2: 6Ψ transcript (228 bp) in all four 6Ψ patients (patients 1--4) but not in the control subject. Bp, base pairs.

1.  Primers directed to exon 5 of the *GHR* gene (forward; AGTGCAACCAGATCCACC) and the junction of exons 6 and 7 (reverse; GGAAAATGATGGACCCTATA) to amplify the wild-type (WT-*GHR*) transcript (Reaction 1).

2.  Primers directed to the *GHR* 6Ψ (forward; GGCACAGATCACTCCCAG) and the junction of exons 7 and 8 (reverse; GATTTCTACTTTCCATGGCTC) to amplify the mutant (6Ψ-*GHR*) transcript (Reaction 2).

Thermocycling conditions were: heated lid 110°C; 30 cycles at 95°C for 30 s, 65°C to 55°C for 30 s and 72°C for 30 s followed by 10 cycles at 95°C for 30 s, 60°C for 30 s and 72°C for 30 s. Products were visualised on a 2% agarose gel and verified by Sanger sequencing (GATC Biotech; <https://www.gatc-biotech.com>).

Quantitative RT-PCR (qRT-PCR)
-----------------------------

The relative levels of WT-*GHR* and 6Ψ-*GHR* mRNA transcripts were quantified by quantitative RT-PCR using the primer sets previously mentioned (Reactions 1 and 2). Expression levels of the two transcripts were determined quantitatively by the MX3000 real-time PCR system (Stratagene) using SYBR green (Kapabiosystems, USA). Ten nanograms of cDNA were added per 10 μL reaction. Thermocycling conditions were: 1 cycle at 95°C for 3 min, 40 cycles at 95°C for 3 s, 60°C for 20 s and 72°C for 10 s and 1 cycle at 95°C for 1 min, 60°C for 30 s and 72°C for 30 s.

The relative expression levels of the two transcripts were compared in the four patients and one control. *Gapdh* was used as the internal reference gene, and five technical repeats for each patient were performed. For each experiment, five independent RNA extractions were assayed with three technical replicates. Relative mRNA expression (stated as mean ± [s.d.]{.smallcaps}) was calculated by delta delta CT analysis (ΔΔCT), and values in patients and control were compared using one-way ANOVA with Bonferroni correction. *P*  value of \< 0.05 was taken as statistical significance.

Genetic analysis by targeted gene sequencing
--------------------------------------------

Genomic DNA was isolated from peripheral blood leukocytes (Qiagen DNeasy Kit) from 11 6Ψ subjects, including patients 1, 2 and 4 from whom skin fibroblasts were obtained. No DNA was available for patient 3. Targeted sequencing of the coding, promotor and intronic regions (2000 bp upstream and 500 bp downstream of each target gene) of 40 short stature genes was undertaken ([Table 1](#tbl1){ref-type="table"}). This was processed on an Illumina HiSeq 2500 sequencing platform with paired end of 100 and a designated average coverage of 100× (Otogenetics, Norcross, GA, USA). The raw data from Otogenetics were analysed using DNA Nexus (DNAnexus Inc., Mountain View, CA, USA) by aligning to the *H. sapiens* GRCh37--b37 (1000 genomes Phase 1) reference genome with BWA-MEM FastQ Readmapper. VCF files were generated by Vendor Human Exome GATK-Lite Variant Caller (Unified Genotyper). Table 1Short stature genes included in the genetic analysis of 11 6Ψ subjects.*GHRIGFBP1SOS2MAP2K1* (*MEK1*)*IGFALSIGFBP2RAF1MAP2K2* (*MEK2*)*STAT5BIGFBP4BRAFA2ML1IGF1IGFBP5NRASLZTR1PAPPA-2IGF2KRASSHOC2IGF1ROBSL1HRASARAFIGFBP3CCDC8RRASNF1PAPPACUL7CBLNPR2STAT3PTPN11RIT1ACANJAK2SOS1RASA2SHOX*[^1]

The resulting VCF files were uploaded to Ingenuity Variant Analysis (Qiagen) and results were analysed with the following filters: call quality ≥20, read depth ≥10 and data outside 5% of most exonically variable 100 base windows in healthy public genomes. Common variants were filtered out by excluding those with a minor allele frequency of ≥0.5% in the 1000 genomes, ExAC and the NHLBI exomes.

Genetic variants were investigated *in silico* by SIFT (score 0, predicted deleterious to 1, predicted benign), PolyPhen-2 (score 0, predicted benign to 1, predicted deleterious) and CADD (Combined Annotation Dependent Depletion) score to predict the functional outcome. The CADD score assesses the negative effect of single nucleotide variants as well as insertion/deletions variants. A scaled CADD score of 20 represents a variant that is among the top 1% deleterious variants, and a scaled CADD score of 30 means that the variant is in the top 0.1%.

Ethical approval
----------------

The study was approved by the Health Research Authority, East of England -- Cambridge East Research Ethics Committee (REC reference: 17/EE/0178). Informed written consent for genetic research, skin biopsy and publication of clinical details was obtained from parents/carers and the patients where appropriate.

Results
=======

Clinical phenotypes
-------------------

The subjects studied had a range of clinical and biochemical heterogeneity as previously described. Patients 1 (height SDS −3.6 and IGF1 SDS −2.0) and 4 (height SDS −3.1 and IGF1 SDS −2.5) were first cousins from a consanguineous Pakistani family with no dysmorphic facial features. Patients 2 (height SDS −4.2 and IGF1 SDS −2.5) and 3 (height SDS −3.8 and IGF1 SDS −2.3) are siblings from another consanguineous Pakistani family. Both had typical facial features of GHI with mid-facial hypoplasia, depressed nasal bridge and prominent forehead. The mean age at presentation of the four patients was 3.2 years (range 2.6--3.8 years) ([Table 2](#tbl2){ref-type="table"}). Table 2Phenotypic features and 6Ψ-*GHR* to WT-*GHR* transcript ratios in the four 6Ψ subjects.PatientSexAge (years)Height SDSIGF1 SDSFacial featuresMean 6Ψ/WT transcript ratio1M3.8−3.6−2.0N39.2:12F3.7−4.2−2.5Y70.7:13M2.6−3.8−2.3Y46.9:14M2.8−3.1−2.5N29.4:1[^2]

The mean age at presentation of the 11 6Ψ patients who underwent targeted gene sequencing was 4.8 years (range 1.2 to 9.9 years), mean height SDS −4.1 (range −3.0 to −5.1 SDS) and mean IGF1 SDS was −2.6 (range −4.0 to −2.0). 10/11 patients and 1/11 patients were from consanguineous Pakistani families and a non-consanguineous Indian family, respectively. Consistent with our previous report ([@bib21]), 6/12 (50%) had facial features of GHI, as previously mentioned.

WT and mutant *GHR* transcript expression
-----------------------------------------

In order to amplify the WT-*GHR* transcript, a RT-PCR reaction was performed (Reaction 1), using primers directed to exon 5 and the junction of exons 6 and 7 of the *GHR* gene ([Fig. 1A](#fig1){ref-type="fig"}). The WT-*GHR* transcript (193 bp) was identified in all four 6Ψ subjects and the control. The 6Ψ-*GHR* transcript was amplified by a RT-PCR reaction (Reaction 2) using primers directed to the *GHR* 6Ψ and the junction of exons 7 and 8 of the *GHR* gene ([Fig. 1A](#fig1){ref-type="fig"}). The mutant 6Ψ-*GHR* transcript (228 bp) was identified in all 6Ψ subjects but not the control ([Fig. 1B](#fig1){ref-type="fig"}). Sanger sequencing verified all the predicted cDNA sequences.

Quantification of the WT and mutant *GHR* transcripts
-----------------------------------------------------

qRT-PCR quantified the relative levels of the WT-*GHR* and mutant 6Ψ*-GHR* transcripts, using the primer sets previously mentioned (Reactions 1 and 2).

WT-*GHR* mRNA expression (mean ± [s.d.]{.smallcaps}) relative to control was 0.055 ± 0.021, 0.022 ± 0.014, 0.055 ± 0.018 and 0.049 ± 0.034 for patients 1--4, respectively ([Fig. 2A](#fig2){ref-type="fig"}). This was significantly lower in all patients compared to control (1.001 ± 0.016); all *P* values \<0.001. This suggests that only small amounts of WT-*GHR* transcript are present in the *GHR* 6Ψ patients.Figure 2Quantitative RT-PCR (qRT-PCR). (A) Box and Whisker plot with jitter showing qRT-PCR of WT*-GHR* mRNA fold change relative to control. Box plots show the mean, upper and lower quartiles and range; IQR = interquartile range; *P* values calculated by one way ANOVA with Bonferroni correction. \*\*\* *P* value \<0.001. (B) Box and Whisker plot with jitter showing qRT-PCR of 6Ψ-*GHR* mRNA fold change relative to Pt 1. Box plots show the mean, upper and lower quartiles and range; IQR = interquartile range; *P* values calculated by one-way ANOVA with Bonferroni correction. \*\*\**P* value \<0.001; \*\**P* value = 0.017. (C) Scatter plot showing the correlation between the height SDS at presentation and the mean 6Ψ:WT transcript ratios in the four 6Ψ patients. Pt, patient; 6Ψ, pseudoexon; WT, wild type; R, Pearson correlation coefficient.

Mutant 6Ψ*-GHR* mRNA expression was calculated relative to patient 1, rather than control, as mutant transcript expression was negligible in the control compared to the 6Ψ subjects. Mutant 6Ψ-*GHR* mRNA expression (mean ± [s.d.]{.smallcaps}) relative to patient 1 (1.003 ± 0.004) were 0.552 ± 0.061, 1.003 ± 0.180 and 0.40 ± 0.069 for patients 2--4, respectively, and 0.001 ± 0.0003 for control. There was no significant difference in 6Ψ-*GHR* transcript levels between patients 1 and 3. However, 6Ψ-*GHR* transcript levels were significantly different between all the other patients (1 and 2, 1 and 4, 2 and 3 and 3 and 4; *P* \< 0.001 and patients 2 and 4; *P* = 0.017) ([Fig. 2B](#fig2){ref-type="fig"}). This confirms variable amounts of mutant 6Ψ*-GHR* transcript in the *GHR* 6Ψ subjects, with negligible levels in control.

The mean 6Ψ:WT transcript ratios for patients 1--4 were 39:1, 71:1, 47:1 and 29:1, respectively ([Table 2](#tbl2){ref-type="table"}). These values correlated negatively with height SDS (R = −0.85, *P* value \<0.001) ([Fig. 2C](#fig2){ref-type="fig"}). This would suggest that shorter patients have transcript ratios in favour of the mutant *GHR*.

Genetic analysis
----------------

We analysed 11 6Ψ subjects (which included patients 1, 2 and 4) for genetic variants in 40 known human short stature genes. This revealed eight predicted deleterious variants in six genes (*IGFALS*, *OBSL1*, *CBL*, *IGF1R*, *ACAN* and*CUL7*) in eight of the 11 6Ψ subjects ([Table 3](#tbl3){ref-type="table"}). Patients 9 and 10 had compound heterozygous missense variants in *CUL7* and *IGFALS*, respectively ([Table 3](#tbl3){ref-type="table"}). The remaining 6/8 variants were monoallelic (patients 2, 4, and 5--8). 4/6 variants were missense and 2/6 variants were in-frame insertions. Of the 8 variants, 6 had a CADD score of \>20. Patients 4 and 6 had in-frame insertions in *CBL* and *IGF1R* genes (CADD score 12.6 and not known, respectively). None of the patients had homozygous variants identified. Table 3Genetic variants identified in known short stature genes in the 6Ψ subjects.PtAge (years)Height SDSIGF-1 SDSGene transcriptTranslationSIFT scorePolyphenCADD scoreACMG/AMP classification13.8−3.6−2.0No deleterious variants detectedN/AN/AN/AN/AN/A23.7−4.2−2.5*ACAN*\
Het c.1223A\>G, p.Q532HMissenseDamagingProbably\
damaging23.7Uncertain significance32.6−3.8−2.3No DNA availableN/AN/AN/AN/AN/A42.8−3.1−2.5*OBSL1*\
Het c.2671A\>G, p.T891AMissenseDamagingProbably\
damaging26.8Uncertain significance*CBL*\
Het c.125_127dupACC, p.H42dupIn-frameNKNK12.6Likely benign55.7−4.5−2.5*OBSL1*\
Het c.2671A\>G, p.T891AMissenseDamagingProbably\
damaging26.8Uncertain significance61.2−4.4−2.2*IGF1R*\
Het c.109_123dupATCGACATCCGCAAC, p.I37_N41dupIn-frameNKNKNKUncertain significance77.0−4.2−2.5*CBL*\
Het c.2216C\>T, p.S739FMissenseDamagingBenign23.1Uncertain significance85.7−3.0−2.9*ACAN*\
Het c.1596G\>C, p.R132CMissenseDamagingProbably\
damaging27.9Uncertain significance94.3−4.1−4.0*CUL7*\
Het c.464G\>A, p.G155E\
c.620G\>A, p.G207EMissenseDamagingProbably\
damaging26.9Uncertain significance102.5−4.4NK*IGFALS*\
Het c.544C\>A, p.L220M\
c.658C\>A, p.L182MMissenseDamagingProbably\
damaging23.5Uncertain significance115.7−4.7−3.1No deleterious variants detectedN/AN/AN/AN/AN/A129.9−5.1−2.1No deleterious variants detectedN/AN/AN/AN/AN/A[^3][^4]

We classified the pathogenicity of the variants according to the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP)'s standards and guidelines for the interpretation of sequence variants ([@bib30]) ([Table 3](#tbl3){ref-type="table"}). Out of the 8 predicted deleterious variants, 7 were variants of 'uncertain significance' ([@bib30]). Although the missense variants are very rare in populations (allele frequency \<0.001 in the gnomAD database ([@bib31])) and in silico variant prediction tools support a deleterious effect on the gene, they fall into the category of 'uncertain significance' as they do not meet the criteria for being either pathogenic or benign ([@bib30]). Furthermore, although the IGF1R heterozygous c.109_123dupATCGACATCCGCAAC, p.I37_N41dup in-frame insertion variant fulfils two moderate criteria for pathogenicity ([@bib30]), that is, protein length changes as a result of in-frame deletion in a non-repeat region and is absent from controls as well as large databases (allele frequency 0.002 in the gnomAD database ([@bib31])), it does not strictly meet the ACMG/AMP criteria for pathogenicity and hence is classified as 'uncertain significance' ([@bib30]). The CBL heterozygous c.125_127dupACC, p.H42dup variant is 'likely benign' ([@bib30]), as it is an in-frame insertion in a repetitive region without known function and there is 1 homozygote in the gnomAD database ([@bib31]).

Patients 2 and 8 with heterozygous ACAN variants did not have advanced bone maturation, early onset osteo-arthritis or intervertebral disc disease. Patient 6 (heterozygous in-frame IGF1R insertion) had normal birth weight, normal IGF-1 SDS, no developmental delay and consequently also did not fulfil the published criteria for the identification of patients with suspected IGF1R mutations (total score \<3) ([@bib32]). Patients 4 and 7 with CBL variants had no cardiac defects or developmental delay. Therefore, although these defects could potentially contribute to the short stature, no phenotypic features associated with these heterozygous genetic defects were detected.

In the four patients who underwent transcript heterogeneity analysis, three underwent genetic sequencing of short stature genes. Patient 2 had a heterozygous missense *ACAN* variant. Patient 4 had a heterozygous missense *OBSL1* variant and a heterozygous in-frame *CBL* variant. Patient 1 had no predicted deleterious variants.

Reviewing all patients assessed on the gene panel ([Table 3](#tbl3){ref-type="table"}; *n* = 11), there was no correlation between the number of predicted deleterious genetic variants (0, 1 or 2) and the degree of short stature (height SDS) in the individual 6Ψ patients, that is, patient 4 had two variants and was not significantly shorter than those with one (*n* = 7) or no variant(s) (*n* = 3) ([Table 3](#tbl3){ref-type="table"}). Additionally, the mean (±[s.d.]{.smallcaps}) height SDS of patients with heterozygous or compound heterozygous variants in autosomal dominant inherited genes (*ACAN*, *CBL* and *IGF1R*) (−3.78 ± 0.67) was not significantly different from that of patients with heterozygous or compound heterozygous variants in autosomal recessive inherited genes (*OBSL*, *CUL7*, *IGFALS*) or patients with no deleterious variants (−4.1 ± 0.56), *P* = 0.39.

Discussion
==========

GH insensitivity (GHI) is a rare disorder caused by mutations in multiple GH-IGF1 axis genes. Homozygous *GHR* mutations are the commonest cause of 'classical' GHI and are associated with a wide range of clinical and biochemical phenotypes ([@bib33]). More recently, it has been noted that several other short stature disorders such as 3M, Noonan Syndrome (NS) and Silver--Russell Syndrome (SRS) overlap with GHI ([@bib2], [@bib34], [@bib35], [@bib36], [@bib37]).

Milder or 'non-classical' GHI cases are being increasingly recognised owing to advent of next generation sequencing techniques and an increased awareness of this group of disorders. Other molecular defects of the GH-IGF1 axis that cause 'non-classical' or milder GHI phenotypes include dominant negative *GHR* ([@bib38], [@bib39], [@bib40], [@bib41]) and STAT5B ([@bib42]) gene mutations, heterozygous IGF1 ([@bib43], [@bib44], [@bib45]), IGF2 ([@bib46], [@bib47]) and IGFALS ([@bib48], [@bib49]) mutations, homozygous PAPPA2 ([@bib6]) mutations and the GHR pseudoexon (6Ψ) mutation ([@bib18], [@bib19], [@bib20], [@bib21]). Non-classical GHI is an important clinical entity and the prevalence may be higher than classical GHI ([@bib2]). Approximately 70 different GHR gene mutations have been reported in more than 300 patients ([@bib1], [@bib2]). A recent UK study ([@bib37]) reporting the genetic diagnoses obtained from candidate gene and whole exome sequencing (WES) in a selected group of 107 patients with GHI showed that the GHR 6Ψ mutation contributed to 25% (8/32) of GHR mutations and 16% (8/51) of all genetic diagnoses.

The GHR 6Ψ mutation is notable, as striking phenotypic variability is observed between different patients harbouring the same homozygous point mutation, even among members of the same kindred ([@bib21]). We hypothesise that several factors, alone or in combination, could contribute to the phenotypic variability observed between individual patients and include: (1.) differences in the levels of mutant vs WT GHR transcripts, (2.) concurrent genetic variants contributing to the degree of growth failure, (3.) environmental factors and (4.) genetic variability in the cellular processes that regulate the mutant and WT-GHR proteins. These are discussed in detail subsequently.

David *et al*. ([@bib19]) suggested that the spectrum of clinical phenotypes observed in the GHR 6Ψ patients may be due to competitive use of both WT and 6Ψ mutant splice sites resulting in different ratios of the two transcripts. The current study tested the hypothesis that transcript heterogeneity could account for the phenotypic differences, particularly the severity of growth failure in the 6Ψ subjects.

We found variable levels of mutant 6Ψ-GHR mRNA expression among all patients except patients 1 and 3, who had similar height deficits of −3.6 and −3.8, respectively. Our work implies that the splicing of the GHR pseudoexon is highly inconsistent, as variable quantities of mutant transcripts are produced in different individuals with the same mutation. Furthermore, consistent with our previous work ([@bib18]), we confirmed the existence of WT-GHR transcript in the 6Ψ subjects alongside the mutated 6Ψ-GHR transcript. This demonstrates that normal as well as abnormal splicing events co-exist in these subjects. Our results also confirm that a higher WT to mutant transcript ratio correlates negatively with the height SDS of the patients, that is, greater mutant pseudoexon inclusion may lead to a more severe phenotype.

Interestingly, consistent with previously published work ([@bib18]), no GHR 6Ψ transcript was detected in the control subject. This would indicate that under normal circumstances, the GHR pseudoexon splice site is not recognised by the splicing machinery, thereby preventing its inclusion in the mature mRNA. This corroborates the work by Akker *et al*. ([@bib8]) who showed that the heterogenous nuclear ribonucleoprotein E1 (hnRNP E1) and small nuclear ribonucleoprotein U1 (snRNP U1) bind to the relatively weak 'wild-type' 5′ GHR pseudoexon splice site in the pre-spliceosomal complex and silence it. The A\>G base change at the 5′ splice site in 6Ψ patients does not create a new splice site but increases the bp match of the pre-mRNA with the snRNP U1. Therefore, the spliceosome recognises the GHR pseudoexon sequence and it is included in the mature mRNA of patients carrying the mutation ([@bib19]).

Genotype-phenotype correlations secondary to variable splicing have been reported in three previous studies. Zhu ([@bib23]) and Lemahieu *et al*. ([@bib34]) investigated the association of different splice mutations of the WASP (Wiskott-Aldrich syndrome protein) gene with the clinical phenotypes of patients with WAS and X-linked thrombocytopaenia. Another study by Gurvich *et al*. ([@bib25]) investigated the correlation between the clinical phenotypes of two patients and the splicing efficiency of two different intronic pseudoexon mutations in the *DMD* (Duchenne muscular dystrophy) gene. All three studies demonstrated that relative amounts of mutant to normal transcripts positively correlated with the severity of the phenotypes of affected individuals. However, these studies examined different splice site mutations of the individual genes. Our work is the first to report the phenotypic impact of transcript heterogeneity in patients with an identical homozygous splice mutation.

The potential underlying mechanism(s) leading to a spectrum of phenotypes in subjects with the same genetic mutation are unclear. Gurvich *et al*. ([@bib25]) proposed that the difference in splicing efficiency between the two different *DMD* gene mutations could be attributed to the strength of the donor splice sites created by the mutation and/or the strength of the cryptic acceptor splice sites in the WT sequence which are further activated by the point mutations. This explanation would not be applicable to our patients, as the 6Ψ intronic point mutation leads to activation of the same 5′ donor splice site in all the subjects.

David *et al*. ([@bib19]) also suggested that the genetic background of individual patients and/or environmental factors may play a role in determining the differential use of WT vs mutant splice sites and thus generation of variable quantities of normal vs mutated transcript. Variations in the core spliceosome machinery (comprising hnRNP and snRNP) and variations in genes encoding RNA processing/RNA-binding factors can influence alternative splicing ([@bib50], [@bib51], [@bib52]). It is possible that differences in these factors between 6Ψ patients regulate the differential use of the mutated and WT splice sites and thus determine the amount of mutant vs WT transcript generated.

It is feasible that the GHI phenotype, particularly the severity of the growth failure observed in the 6Ψ patients, is influenced by genetic variants in different genetic loci. We sought concurrent defects in genes known to cause short stature, GH insensitivity and overlapping phenotypes, for example, Noonan, Silver--Russell and 3M Syndrome in 11 6Ψ patients.

Analysis of 40 genes (including intronic and promoter regions) revealed that a significant proportion (73%) of 6Ψ subjects had predicted deleterious heterozygous or compound heterozygous genetic variants. Of these, three variants in ACAN, IGF1R and CBL genes are recognised to have an autosomal dominant pattern of inheritance leading to short stature ([@bib53], [@bib54], [@bib55]). It is possible that these variants contributed to the growth failure in patients 2, 4, 6, 7 and 8. However, none of these patients had additional phenotypic features that would be consistent with the identified additional genetic variant. Furthermore, there was no difference in height SDS between the patients with heterozygous/compound heterozygous variants in genes with an autosomal dominant pattern of inheritance compared to patients with heterozygous/compound heterozygous variants in genes with an autosomal recessive inheritance or patients with no deleterious variants. This implies that the *ACAN*, *IGF1R* and *CBL* gene variants identified did not impact significantly on the patient's phenotypes. Unfortunately, we were unable to perform segregation studies as parental DNA was not available for any of the subjects. However, consistent with our findings, a previous study of two 6Ψ patients also demonstrated that other genetic variants did not contribute to the severity of the phenotypes ([@bib20]).

Interestingly, given that the majority of patients have consanguineous family structures, no homozygous variants were detected. We were also unable to identify a correlation between the number of predicted deleterious variants and the severity of short stature in the individual GHR 6Ψ patients studied. This indicates that concurrent defects in this subset of known short stature, GHI and overlapping disorders genes do not appear to contribute to the growth phenotype in these patients. We cannot, however, rule out an impact of other known short stature genes or currently undiscovered short stature genes. It is also possible that multiple genes with smaller effect size could account for some or all of the clinical variation.

Genotyping a region spanning 17.10 Mb around the GHR gene on chromosome 5 and analysis of the complex single polymorphic region in intron 9 of the GHR in five GHR 6Ψ families showed the same genotype for all affected members, suggesting the presence of a common ancestor ([@bib19]). Furthermore, 19/22 of the known GHR pseudoexon patients are of Pakistani ethnicity ([@bib18], [@bib19], [@bib20], [@bib21]). This implies that the *GHR* 6Ψ patient cohort share a common genetic background. This is comparable to the p.E180 splice *GHR* mutation found predominantly in individuals from Ecuador, Brazil and Chile, where a shared genetic background flanking the splice mutation was identified ([@bib56], [@bib57]). First degree relatives who are heterozygous carriers of the p.E180 mutation are modestly shorter than non-carrier relatives ([@bib58]). This is in contrast to our cohort, where heterozygous carrier parents of 6Ψ patients had normal stature ([@bib19]).

It is recognised that a multitude of environmental factors such as nutrition, socio-economic status and adverse environmental conditions affect childhood growth ([@bib59], [@bib60]). It is possible that any of these factors contribute to the phenotypic variability observed in our patient cohort. However, as there are marked differences between affected individuals within the same kindred, environmental factors are unlikely to be very significant.

It is feasible that differences in processing, trafficking and degradation of the mutant and WT GH receptor proteins account for the clinical differences ([@bib19]). Maamra *et al*. ([@bib22]) confirmed that the mutant GHR 6Ψ protein compromised normal cell surface trafficking but signalling was unimpaired. Therefore, variability in genes regulating these cellular processes might conceivably have a greater influence on the mutant 6Ψ GHR protein than the WT GHR. Further work exploring this hypothesis is required.

It is important to acknowledge that our study has several limitations. First, GHR transcript ratios were studied in only four 6Ψ patients. Furthermore, one of the four patients was not assessed on the gene panel. Our work would not identify variants in other known short stature genes not included in the panel or defects in currently undiscovered short stature genes. Additionally, the phenotypic spectrum of individual genetic defects is expected to broaden as more patients are reported. Finally, we did not explore the mechanisms underlying the observed variable splicing or genetic variability which might affect GHR protein processing, trafficking and degradation. Further work is required to address these.

In conclusion, our work shows that there is a variable ratio of mutated and WT-GHR mRNA transcripts in GHR 6Ψ patients. The mutated GHR 6Ψ transcript is not normally spliced in unaffected subjects. Patients with more severe phenotypes, that is, lower height SDS, have a GHR transcript ratio in favour of the mutant GHR. The reason for the variable splicing in different patients with the same mutation is fascinating. The genetic background of individuals may influence this. However, our preliminary work does not suggest that variants in candidate SS genes contribute significantly to the variability of growth failure. This is the first indication that variable splicing and transcript heterogeneity can lead to a range of short stature phenotypes in subjects harbouring the same genetic mutation.
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[^1]: Genetic analysis included review of known (*GHR*, *IGFALS*, *STAT5B*, *IGF1*, *PAPPA2* and *IGF1R*) and putative (*IGFBP3*, *PAPPA*, *STAT3*, *JAK2*, *IGFBP1*, *IGFBP2*, *IGFB4* and *IGFBP5*) monogenic defects of the GH-IGF1 axis leading to GHI and IGF1 resistance phenotypes. We also sought variants in genes associated with overlapping short stature syndromes ([@bib2], [@bib34], [@bib35], [@bib36], [@bib37]) 3M (*OBSL1*, *CCDC8* and *CUL7*), Silver--Russell (*IGF2*) and Noonan (*PTPN11*, *SOS1*, *SOS2*, *RAF1*, *BRAF*, *NRAS*, *KRAS*, *HRAS*, *RRAS*, *CBL*, *RIT1*, *RASA2*, *MAP2K1*, *MAP2K2*, *A2ML1*, *LZTR1*, *SHOC2*, *ARAF* and *NF2*) syndromes. Other genes associated with short stature (*ACAN* ([@bib61], [@bib62]), *NPR2* ([@bib63]) and *SHOX* ([@bib64])) were also included in the analysis.

[^2]: 6Ψ, mutant pseudoexon transcript; F, female; Facial features, facial features of classical GHI (frontal bossing, mid-facial hypoplasia); M, male; N, no; WT, wild type GHR transcript; Y, yes.

[^3]: Patients 1--4 are the 6Ψ patients analysed for WT-*GHR* and 6Ψ-*GHR* transcript ratios (Table 2).

[^4]: ACMG/AMP classification, classification as per the American College of Medical Genetics and Genomics and the Association for Molecular Pathology's standards and guidelines for the interpretation of sequence variants; c., coding DNA sequence where nucleotide 1 is the A of the ATG-translation initiation codon (NCBI reference sequences: for ACAN, NM_013227.2; for OBSL1, NM_015311.2; for CBL, NM_005188.3; for IGF1R, NM_000875.3; for CUL7, NM_001168370.1 and for IGFALS, NM_004970.2); CADD, combined annotation dependent depletion; Ht, height; N/A, not applicable; NK, not known; Pt, patient ([@bib30]).
